General Information of the Drug (ID: M6APDG00236)
Name
8-Oxo-8-phenyl-octanoic acid hydroxyamide
Synonyms
CHEMBL95959; 8-Oxo-8-phenyl-octanoic acid hydroxyamide; SCHEMBL3383197; N-hydroxy-8-oxo-8-phenyloctanamide
    Click to Show/Hide
Status
Investigative
Structure
Formula
C14H19NO3
InChI
1S/C14H19NO3/c16-13(12-8-4-3-5-9-12)10-6-1-2-7-11-14(17)15-18/h3-5,8-9,18H,1-2,6-7,10-11H2,(H,15,17)
InChIKey
DPHGSTLAQCKOFV-UHFFFAOYSA-N
PubChem CID
11075845
TTD Drug ID
D0S0WK
Target Gene(s) and Their Upstream m6A Regulator, Together with the Effect of Target Gene(s) in Drug Response
The target genes involved in drug-target interaction (such as drug-metabolizing enzymes, drug transporters and therapeutic targets) and drug-mediated cell death signaling (including modulating DNA damage and repair capacity, escaping from drug-induced apoptosis, autophagy, cellular metabolic reprogramming, oncogenic bypass signaling, cell microenvironment, cell stemness, etc.) could be regulated by m6A regulator(s) and affected their corresponding drug response. You can browse detailed information on drug-related target gene(s) mediated by m6A regulators.
Histone deacetylase 2 (HDAC2)
Methyltransferase-like 3 (METTL3)
In total 1 mechanisms lead to this potential drug response
Response Summary Histone deacetylase 2 (HDAC2) is a therapeutic target for 8-Oxo-8-phenyl-octanoic acid hydroxyamide. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 8-Oxo-8-phenyl-octanoic acid hydroxyamide through regulating the expression of Histone deacetylase 2 (HDAC2). [1], [2]
References
Ref 1 The epitranscriptome m6A writer METTL3 promotes chemo- and radioresistance in pancreatic cancer cells. Int J Oncol. 2018 Feb;52(2):621-629. doi: 10.3892/ijo.2017.4219. Epub 2017 Dec 7.
Ref 2 N-Hydroxy-(4-oxime)-cinnamide: a versatile scaffold for the synthesis of novel histone deacetylase [correction of deacetilase] (HDAC) inhibitors. Bioorg Med Chem Lett. 2009 Apr 15;19(8):2346-9. doi: 10.1016/j.bmcl.2009.02.029. Epub 2009 Feb 12.